ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,205,857 | -66.0% | 107,955 | -34.9% | 0.00% | -100.0% |
| Q2 2023 | $3,547,970 | -47.7% | 165,793 | -1.1% | 0.00% | 0.0% |
| Q1 2023 | $6,781,909 | -13.4% | 167,703 | -0.4% | 0.00% | -50.0% |
| Q4 2022 | $7,834,851 | -13.3% | 168,419 | -3.3% | 0.00% | 0.0% |
| Q3 2022 | $9,035,000 | +13.9% | 174,179 | +3.8% | 0.00% | 0.0% |
| Q2 2022 | $7,931,000 | -39.0% | 167,795 | -8.2% | 0.00% | -33.3% |
| Q1 2022 | $13,004,000 | -11.0% | 182,701 | -6.5% | 0.00% | 0.0% |
| Q4 2021 | $14,617,000 | +40.3% | 195,461 | +6.6% | 0.00% | +50.0% |
| Q3 2021 | $10,416,000 | +34.2% | 183,342 | +4.0% | 0.00% | 0.0% |
| Q2 2021 | $7,761,000 | -19.0% | 176,373 | -9.3% | 0.00% | 0.0% |
| Q1 2021 | $9,586,000 | +17.9% | 194,382 | +0.7% | 0.00% | 0.0% |
| Q4 2020 | $8,129,000 | -9.7% | 193,094 | -1.8% | 0.00% | 0.0% |
| Q3 2020 | $9,004,000 | -6.3% | 196,683 | +2.8% | 0.00% | -33.3% |
| Q2 2020 | $9,609,000 | +1.1% | 191,372 | +3.6% | 0.00% | 0.0% |
| Q1 2020 | $9,503,000 | -18.8% | 184,775 | -2.4% | 0.00% | 0.0% |
| Q4 2019 | $11,697,000 | -0.8% | 189,317 | -3.5% | 0.00% | 0.0% |
| Q3 2019 | $11,793,000 | -28.5% | 196,283 | +0.4% | 0.00% | -40.0% |
| Q2 2019 | $16,499,000 | -32.6% | 195,534 | -23.7% | 0.01% | -28.6% |
| Q1 2019 | $24,487,000 | +35.7% | 256,357 | +0.6% | 0.01% | +16.7% |
| Q4 2018 | $18,045,000 | -17.7% | 254,763 | -0.7% | 0.01% | 0.0% |
| Q3 2018 | $21,917,000 | -23.3% | 256,446 | +4.0% | 0.01% | -25.0% |
| Q2 2018 | $28,587,000 | +41.7% | 246,647 | -1.1% | 0.01% | +33.3% |
| Q1 2018 | $20,177,000 | +97.5% | 249,376 | +43.2% | 0.01% | +100.0% |
| Q4 2017 | $10,218,000 | +21.3% | 174,114 | -3.2% | 0.00% | +50.0% |
| Q3 2017 | $8,421,000 | +21.9% | 179,946 | -6.3% | 0.00% | 0.0% |
| Q2 2017 | $6,907,000 | +12.6% | 191,982 | -3.6% | 0.00% | 0.0% |
| Q1 2017 | $6,132,000 | -5.7% | 199,078 | +2.6% | 0.00% | 0.0% |
| Q4 2016 | $6,501,000 | +27.8% | 194,056 | +1.5% | 0.00% | 0.0% |
| Q3 2016 | $5,087,000 | +22.9% | 191,157 | +1.8% | 0.00% | +100.0% |
| Q2 2016 | $4,140,000 | -37.1% | 187,741 | -16.3% | 0.00% | -50.0% |
| Q1 2016 | $6,585,000 | -34.2% | 224,181 | -26.0% | 0.00% | -33.3% |
| Q4 2015 | $10,000,000 | -14.9% | 302,854 | -6.9% | 0.00% | -25.0% |
| Q3 2015 | $11,756,000 | +28.5% | 325,290 | +60.0% | 0.00% | +33.3% |
| Q2 2015 | $9,147,000 | +83.9% | 203,294 | +25.2% | 0.00% | +200.0% |
| Q1 2015 | $4,973,000 | +35.1% | 162,390 | +124.3% | 0.00% | 0.0% |
| Q4 2014 | $3,682,000 | +38.5% | 72,389 | +7.7% | 0.00% | 0.0% |
| Q3 2014 | $2,659,000 | -45.5% | 67,217 | -40.7% | 0.00% | 0.0% |
| Q2 2014 | $4,882,000 | +37.6% | 113,342 | +27.8% | 0.00% | 0.0% |
| Q1 2014 | $3,547,000 | +48.3% | 88,691 | +1.2% | 0.00% | 0.0% |
| Q4 2013 | $2,391,000 | -22.6% | 87,640 | -35.0% | 0.00% | – |
| Q3 2013 | $3,090,000 | +896.8% | 134,802 | +670.4% | 0.00% | – |
| Q2 2013 | $310,000 | – | 17,497 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |